ArticleDiabetic medicine : a journal of the British Diabetic Association2026
Mind the gap: Ongoing inequalities in glycaemic levels in young people living with Type 1 diabetes across England and Wales.
Article in Diabetic medicine : a journal of the British Diabetic Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD).Diabetic medicine : a journal of the British Diabetic Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsInequalities in glycaemic levels in children and young people (CYP) living with Type 1 diabetes (T1D) across different ethnic and socio-economic groups in England and Wales were first highlighted in 2016. Almost 10 years on, we wanted to know if the gap has been closed.
methodsAnalysis of 27,919 CYP with T1D from the 2022-2023 National Paediatric Diabetes Audit (NPDA). Multivariable linear regression was used to assess any association between socio-economic status (SES), ethnicity or insulin pump use and HbA1c, adjusting for age, gender and diabetes duration.
resultsCYP from ethnic minority groups continue to have significantly higher mean HbA1c levels compared to White CYP with the largest difference in Black children (6.8 mmol/mol, [0.6%], 95% CI 5.7, 7.9 mmol/mol). Lower SES remains associated with higher HbA1c levels with the largest difference between the least deprived and most deprived (7.0 mmol/mol; [0.6%], 95% CI: 6.4, 7.6). CYP from ethnic minority groups (Black 34.2% vs. White 49.56%, p < 0.0001) and those living in more deprived neighbourhoods (Least Deprived 54% vs. Most Deprived 41%, p = 0.0001) were less likely to use insulin pumps.
conclusionsEthnicity and SES remained significantly associated with HbA1c levels even after accounting for the use of insulin pumps. Black CYP continue to have the highest glycaemic levels, and lower SES remains associated with poorer HbA1c outcomes. Substantial inequalities persist in the use of insulin pump therapy highlighting the ongoing need for targeted interventions to improve equity in diabetes care and outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.